How to solve the problem of hypersensitivity to asparaginase?

Ching-Hon Pui^{1

2}, Yiwei Liu³, Mary V Relling^{3

4}

Affiliations

¹ Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
² College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
³ Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
⁴ College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee.

Comment

Ching-Hon Pui et al. Pediatr Blood Cancer. 2018 Mar.

. 2018 Mar;65(3):10.1002/pbc.26884.

doi: 10.1002/pbc.26884. Epub 2017 Nov 22.

Ching-Hon Pui^{1

2}, Yiwei Liu³, Mary V Relling^{3

4}

¹ Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
² College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
³ Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
⁴ College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee.

No abstract available

Conflict of interest statement

Conflict of Interest: None

Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE, Dreyer Z, Choi MR, Liang W, Skowronski R, Allamneni KP, Devidas M, Raetz EA, Adamson PC, Blaney SM, Loh ML, Hunger SP. Rau RE, et al. Pediatr Blood Cancer. 2018 Mar;65(3):10.1002/pbc.26873. doi: 10.1002/pbc.26873. Epub 2017 Nov 1. Pediatr Blood Cancer. 2018. PMID: 29090524 Free PMC article. Clinical Trial.

1. Yen HJ, Chang WH, Liu HC, et al. Outcomes following discontinuation of E. coli l-asparaginase upon severe allergic reactions in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:665–70. - PubMed
1. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31:1202–1210. - PMC - PubMed
1. Vrooman LM, Kirov II, Dreyer ZE, et al. Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:228–233. - PMC - PubMed
1. Salles G, Le Gouill S, Rigal-Huguet F, et al. A Phase 1 dose-escalation study of pegcrisantaspase administered by intravenous Infusion in adult patients with relapsed or refractory hematological malignancies. Pediatr Blood Cancer. 2014;61:S209.
1. Rau RE, Dreyer Z, Choi MR, et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinase, pegcrisantaspase: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2017 (in press) - PMC - PubMed